Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
INO Inovio Pharmaceuticals	$1.93 -5.9%	$2.04	$1.74 ▼ $14.75	$50.37M	0.92	537,498 shs	394,652 shs
MRNA Moderna	$34.30 -2.0%	$36.09	$29.25 ▼ $170.47	$13.23B	1.86	12.49 million shs	9.42 million shs
NVAX Novavax	$8.17 +0.9%	$8.45	$3.81 ▼ $23.86	$1.31B	2.92	8.04 million shs	3.02 million shs
PFE Pfizer	$25.60 -0.4%	$26.26	$24.48 ▼ $31.54	$145.08B	0.61	40.06 million shs	36.67 million shs
VALN Valneva	$6.79 -3.4%	$6.06	$3.62 ▼ $9.50	$551.76M	1.93	25,832 shs	11,335 shs

Beginner's Guide To Retirement Stocks

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
INO Inovio Pharmaceuticals	+5.13%	+4.06%	+6.77%	-45.48%	-82.19%
MRNA Moderna	+3.70%	-0.57%	+9.85%	-18.24%	-68.30%
NVAX Novavax	+2.27%	+2.66%	-1.10%	-10.20%	+60.08%
PFE Pfizer	-1.05%	-0.78%	-0.54%	+1.40%	-8.16%
VALN Valneva	-0.42%	-0.42%	+0.43%	+78.88%	-6.02%

Remove Ads

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
INO Inovio Pharmaceuticals	3.5446 of 5 stars	3.3	1.0	0.0	4.3	2.0	0.0	1.3
MRNA Moderna	4.174 of 5 stars	4.0	1.0	0.0	4.6	2.1	2.5	0.6
NVAX Novavax	3.6319 of 5 stars	3.2	1.0	0.0	4.7	1.9	1.7	0.6
PFE Pfizer	4.972 of 5 stars	3.3	3.0	4.2	4.2	2.8	3.3	3.1
VALN Valneva	2.7654 of 5 stars	3.5	5.0	0.0	0.0	3.1	0.8	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
INO Inovio Pharmaceuticals	2.60	Moderate Buy	$12.40	542.49% Upside
MRNA Moderna	2.04	Hold	$59.60	73.76% Upside
NVAX Novavax	2.43	Hold	$18.00	120.32% Upside
PFE Pfizer	2.59	Moderate Buy	$31.92	24.70% Upside
VALN Valneva	3.00	Buy	$17.00	150.37% Upside

Current Analyst Ratings Breakdown

Latest NVAX, PFE, MRNA, VALN, and INO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
3/13/2025	MRNA Moderna	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Neutral	$40.00
3/12/2025	PFE Pfizer	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
3/10/2025	PFE Pfizer	Hsbc Global Res Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
2/28/2025	NVAX Novavax	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$19.00
2/28/2025	VALN Valneva	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$17.00 ➝ $17.00
2/27/2025	NVAX Novavax	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold
2/19/2025	MRNA Moderna	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$96.00 ➝ $78.00
2/19/2025	VALN Valneva	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$18.00 ➝ $17.00
2/18/2025	MRNA Moderna	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sector Perform ➝ Sector Perform	$40.00 ➝ $40.00
2/18/2025	MRNA Moderna	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Overweight ➝ Equal Weight	$111.00 ➝ $45.00
2/14/2025	MRNA Moderna	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$45.00

(Data available from 3/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
INO Inovio Pharmaceuticals	$203.41K	247.64	N/A	N/A	$5.16 per share	0.37
MRNA Moderna	$3.20B	4.14	N/A	N/A	$28.33 per share	1.21
NVAX Novavax	$682.16M	1.93	N/A	N/A	($6.04) per share	-1.35
PFE Pfizer	$63.63B	2.28	$4.01 per share	6.38	$15.81 per share	1.62
VALN Valneva	$158.54M	3.48	N/A	N/A	$2.00 per share	3.40

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
INO Inovio Pharmaceuticals	-$135.12M	-$2.10	N/A	N/A	N/A	N/A	-118.17%	-83.47%	5/12/2025 (Estimated)
MRNA Moderna	-$3.56B	-$9.28	N/A	N/A	N/A	-110.04%	-28.74%	-21.83%	5/1/2025 (Estimated)
NVAX Novavax	-$545.06M	-$1.33	N/A	102.13	2.85	-32.18%	N/A	-17.05%	5/9/2025 (Estimated)
PFE Pfizer	$8.03B	$1.41	18.16	8.45	0.64	12.62%	19.47%	8.09%	4/29/2025 (Estimated)
VALN Valneva	-$109.78M	-$0.13	N/A	N/A	N/A	-4.35%	-3.93%	-1.42%	3/19/2025 (Estimated)

Latest NVAX, PFE, MRNA, VALN, and INO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
3/19/2025	N/A	VALN Valneva	-$0.22	N/A	N/A	N/A	$55.64 million	N/A
2/27/2025	Q4 24	NVAX Novavax	-$0.75	-$0.51	+$0.24	-$0.51	$85.48 million	$88.31 million
2/4/2025	Q4 2024	PFE Pfizer	$0.48	$0.63	+$0.15	$0.07	$17.26 billion	$17.76 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
INO Inovio Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
MRNA Moderna	N/A	N/A	N/A	N/A	N/A
NVAX Novavax	N/A	N/A	N/A	N/A	N/A
PFE Pfizer	$1.72	6.72%	+2.50%	121.99%	16 Years
VALN Valneva	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
INO Inovio Pharmaceuticals	N/A	3.88	3.88
MRNA Moderna	N/A	3.67	3.62
NVAX Novavax	N/A	0.93	0.93
PFE Pfizer	0.63	1.00	0.73
VALN Valneva	0.70	2.78	2.25

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
INO Inovio Pharmaceuticals	26.79%
MRNA Moderna	75.33%
NVAX Novavax	53.04%
PFE Pfizer	68.36%
VALN Valneva	11.39%

Insider Ownership

Company	Insider Ownership
INO Inovio Pharmaceuticals	2.50%
MRNA Moderna	15.70%
NVAX Novavax	1.00%
PFE Pfizer	0.06%
VALN Valneva	14.91%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
INO Inovio Pharmaceuticals	320	26.10 million	25.45 million	Optionable
MRNA Moderna	5,600	385.82 million	324.40 million	Optionable
NVAX Novavax	1,543	160.84 million	158.58 million	Optionable
PFE Pfizer	88,000	5.67 billion	5.66 billion	Optionable
VALN Valneva	700	81.26 million	69.15 million	Not Optionable

NVAX, PFE, MRNA, VALN, and INO Headlines

Recent News About These Companies

Valneva SE (NASDAQ:VALN) Short Interest Down 84.2% in February

March 13 at 3:52 PM | marketbeat.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valneva SE - VALN

March 13 at 1:00 PM | accessnewswire.com

Bronstein, Gewirtz & Grossman, LLC Encourages Valneva SE (VALN) Stockholders to Inquire about Securities Investigation

March 13 at 10:00 AM | accessnewswire.com

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Valneva SE (VALN) and Encourages Investors to Learn More About the Investigation

March 12 at 10:00 AM | accessnewswire.com

Valneva (VALN) Expected to Announce Earnings on Wednesday

March 12 at 2:32 AM | marketbeat.com

Valneva SE (VALN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

March 11 at 4:21 PM | markets.businessinsider.com

Bronstein, Gewirtz & Grossman, LLC Is Investigating Valneva SE (VALN) And Encourages Investors to Connect

March 10 at 10:00 AM | accessnewswire.com

Bronstein, Gewirtz & Grossman, LLC Is Investigating Valneva SE (VALN) And Encourages Stockholders to Connect

March 9, 2025 | accessnewswire.com

Valneva (NASDAQ:VALN) Shares Gap Up - Here's Why

March 8, 2025 | marketbeat.com

Valneva SE (VALN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

March 7, 2025 | accessnewswire.com

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Valneva SE (VALN) and Encourages Stockholders to Learn More About the Investigation.

March 6, 2025 | accessnewswire.com

ATTENTION VALN SHAREHOLDERS: Investors who lost money on Valneva SE are urged to contact Levi & Korsinsky about an ongoing investigation

March 5, 2025 | accessnewswire.com

Bronstein, Gewirtz & Grossman, LLC Encourages Valneva SE (VALN) Investors to Inquire about Securities Investigation

March 5, 2025 | accessnewswire.com

Valneva SE Being Investigated on Behalf of Valneva SE Investors. Contact Levi & Korsinsky For Details.

March 4, 2025 | accessnewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valneva SE - VALN

March 4, 2025 | prnewswire.com

Levi & Korsinsky Reminds Shareholders of an Investigation into Valneva SE (VALN) Regarding Potential Securities Fraud Allegations

March 4, 2025 | accessnewswire.com

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Valneva SE (VALN) And Encourages Investors to Reach Out

March 4, 2025 | accessnewswire.com

Valneva SE to Present at Key Healthcare Investor Conferences

March 3, 2025 | tipranks.com

Valneva to Present at Upcoming TD Cowen and Van Lanschot Kempen Healthcare Investor Conferences

March 3, 2025 | globenewswire.com

Valneva Receives EMA's Positive CHMP Opinion for Adolescent Label Extension for Chikungunya Vaccine IXCHIQ

March 2, 2025 | finanznachrichten.de

HC Wainwright Reaffirms "Buy" Rating for Valneva (NASDAQ:VALN)

March 1, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Price Targets on NVIDIA Rise in Front of Earnings
By Sarah Horvath | February 24, 2025
View Price Targets on NVIDIA Rise in Front of Earnings
Warren Buffett Swaps VOO for This Reliable Dividend Stock
By Sarah Horvath | March 7, 2025
View Warren Buffett Swaps VOO for This Reliable Dividend Stock
NVIDIA’s Hidden AI Play: The Truth Behind Its WeRide Investment
By Gabriel Osorio-Mazilli | February 14, 2025
View NVIDIA’s Hidden AI Play: The Truth Behind Its WeRide Investment
Moderna: 4 Key Reasons the CEO Just Bought $5M in Shares
By Jea Yu | March 11, 2025
View Moderna: 4 Key Reasons the CEO Just Bought $5M in Shares
Moderna: A Generational Opportunity for Investors in 2025
By Thomas Hughes | February 19, 2025
View Moderna: A Generational Opportunity for Investors in 2025

NVAX, PFE, MRNA, VALN, and INO Company Descriptions

Inovio Pharmaceuticals NASDAQ:INO

$1.93 -0.12 (-5.85%)

Closing price 04:00 PM Eastern

Extended Trading

$1.97 +0.04 (+2.07%)

As of 07:53 PM Eastern

Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. Its products in pipeline include VGX-3100 for the treatment of HPV-related cervical high-grade dysplasia; INO-3107 for HPV-related recurrent respiratory papillomatosis and is under Phase 1/2 trial; INO-3112 for the treatment of HPV-related Oropharyngeal Squamous Cell Carcinoma and is under Phase 2 trial; INO-5401 for the treatment of glioblastoma multiforme and is under Phase 2 trial; INO-4201 for Ebola Virus Disease and is under Phase 1b trial; INO-4800 for COVID-19 and is under Phase 3 trial; and INO-6160 for the treatment of human immunodeficiency virus and is under Phase 1 trial. Its partners and collaborators include Advaccine Biopharmaceuticals Suzhou Co, ApolloBio Corporation, AstraZeneca, The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations, Defense Advanced Research Projects Agency, The U.S. Department of Defense, HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Richter-Helm BioLogics, Thermo Fisher Scientific, the University of Pennsylvania, the Walter Reed Army Institute of Research, and The Wistar Institute. The company was incorporated in 1983 and is headquartered in Plymouth Meeting, Pennsylvania.

Moderna NASDAQ:MRNA

$34.30 -0.71 (-2.03%)

Closing price 04:00 PM Eastern

Extended Trading

$34.55 +0.25 (+0.73%)

As of 07:59 PM Eastern

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Novavax NASDAQ:NVAX

$8.17 +0.07 (+0.86%)

Closing price 04:00 PM Eastern

Extended Trading

$8.19 +0.02 (+0.24%)

As of 07:59 PM Eastern

Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 influenza combination. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It is also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.

Pfizer NYSE:PFE

$25.60 -0.11 (-0.43%)

Closing price 03:59 PM Eastern

Extended Trading

$25.64 +0.04 (+0.14%)

As of 07:59 PM Eastern

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Valneva NASDAQ:VALN

$6.79 -0.24 (-3.41%)

Closing price 03:59 PM Eastern

Extended Trading

$6.78 0.00 (-0.07%)

As of 04:10 PM Eastern

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine. The company also develops VLA15, a vaccine candidate, which is in Phase III clinical trial against Borrelia, the bacterium that causes Lyme disease; VLA1553, a vaccine candidate, which is in Phase III clinical trial against the chikungunya virus; VLA1554, a vaccine candidate targeting human metapneumovirus; and VLA2112, a vaccine candidate to treat patients with epstein-barr virus. It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, France, rest of European countries, and internationally. Valneva SE has collaborations with Pfizer, Inc. to co-develop and commercialize its Lyme disease vaccine; and Instituto Butantan for the development, manufacturing, and marketing of single-shot chikungunya vaccine. The company was founded in 1998 and is based in Saint-Herblain, France.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time